Ultra Drugs Profile
Key Indicators
- Authorised Capital ₹ 3.50 Cr
as on 15-11-2024
- Paid Up Capital ₹ 3.06 Cr
as on 15-11-2024
- Company Age 19 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 26.40 Cr
as on 15-11-2024
- Satisfied Charges ₹ 26.77 Cr
as on 15-11-2024
- Revenue 4.20%
(FY 2023)
- Profit -47.18%
(FY 2023)
- Ebitda -20.65%
(FY 2023)
- Net Worth 7.96%
(FY 2023)
- Total Assets 13.75%
(FY 2023)
About Ultra Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.50 Cr and a paid-up capital of Rs 3.06 Cr.
The company currently has active open charges totaling ₹26.40 Cr. The company has closed loans amounting to ₹26.77 Cr, as per Ministry of Corporate Affairs (MCA) records.
Minna Jakhar, Sandeep Arora, and Sangram Singh serve as directors at the Company.
- CIN/LLPIN
U24230CH2005PTC029023
- Company No.
029023
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Oct 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Ultra Drugs Private Limited offer?
Ultra Drugs Private Limited offers a wide range of products and services, including Common Disease Medicines, Herbal Cough Syrup, Digestive System Drugs & Medicines, Antacid Drugs, Pain Relief Drugs & Pharmaceuticals, Aceclofenac, Pharma & Bioanalytical Services, Pharmaceutical Third Party Manufacturing, Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops.
Who are the key members and board of directors at Ultra Drugs?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sangram Singh  | Director | 30-Sep-2006 | Current |
| Sandeep Arora | Director | 25-Oct-2017 | Current |
| Minna Jakhar | Director | 14-Jan-2008 | Current |
Financial Performance of Ultra Drugs.
Ultra Drugs Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 4.2% increase. The company also saw a substantial fall in profitability, with a 47.18% decrease in profit. The company's net worth moved up by a moderate rise of 7.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ultra Drugs?
In 2023, Ultra Drugs had a promoter holding of 100.00%. The company had 3 Subsidiaries and 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ultra Drugs Formulations Private LimitedActive 4 years 10 monthsMinna Jakhar, Sandeep Arora and 1 more are mutual person
Ultra Bytes Private LimitedActive 9 years 7 monthsMinna Jakhar, Sandeep Arora and 1 more are mutual person
- Dakhson Research & Development Foundation.Active 16 years 7 months
Minna Jakhar and Sangram Singh are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 24 Jan 2023 | ₹17.50 Cr | Open |
Hdfc Bank Limited Creation Date: 29 Aug 2021 | ₹1.00 Cr | Open |
Hdfc Bank Limited Creation Date: 03 Mar 2021 | ₹1.00 M | Open |
How Many Employees Work at Ultra Drugs?
Ultra Drugs has a workforce of 506 employees as of Sep 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ultra Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ultra Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
